Physician profile
Erin E Thornton
NPI 1598869992
$7,891.51
in general payments reported to CMS, 2019-2025
28 companies · $2,393 in 2025
The $2,393 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $781 · 2022: $990 · 2023: $1,063 · 2024: $2,664 · 2025: $2,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,862 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,862.30 |
| Education | $258.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,883.04 | 2021-2025 | |
| Janssen Biotech, INC. | $1,005.22 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $800.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $755.95 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $492.95 | 2021-2025 | Blu-U |
| Amgen INC. | $463.91 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $402.10 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $369.22 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $340.74 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $232.36 | 2021-2025 | |
| Dermavant Sciences, INC. | $216.06 | 2022-2024 | Vtama |
| Leo Pharma INC. | $210.08 | 2021-2025 | Adbry, Anzupgo |
| Kerecis Limited | $130.38 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Abiomed | $88.44 | 2024 | Impella |
| Ucb, INC. | $80.88 | 2024-2025 | Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $79.99 | 2021-2023 | Xolair |
| Almirall LLC | $59.38 | 2021-2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.39 | 2021-2024 | Arazlo |
| Galderma Laboratories, L.P. | $57.53 | 2021-2025 | Nemluvio |
| Convatec INC. | $30.68 | 2024 | |
| Integra Lifesciences Corporation | $22.83 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Dermira, INC. | $20.31 | 2021 | |
| Reprise Biomedical, INC. | $17.76 | 2025 | Miro3d |
| Verrica Pharmaceuticals INC. | $16.30 | 2024 | Ycanth |
| Sandoz INC. | $15.72 | 2021 | |
| Organon LLC | $14.71 | 2025 | Vtama |
| Journey Medical Corporation | $14.24 | 2022 | |
| Allergan, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.